FORECAST: ABA: Abano acquisition update and guidance
31 Mar 2010 8:30 am
ABA
31/03/2010
FORECAST
REL: 0830 HRS Abano Healthcare Group Limited
FORECAST: ABA: Abano acquisition update and guidance
ABANO CONTINUES TO ROLL OUT ITS ESTABLISHED ACQUISITION AND GROWTH STRATEGY
AND PROVIDES GUIDANCE FOR THE FULL YEAR
Following the sale of Bay Audiology in New Zealand, listed healthcare
investor and operator, Abano Healthcare Group, has continued to expand in the
second half of the 2010 financial year, with a number of new acquisitions and
organic growth in targeted healthcare sectors.
Abano's Dental sector now plays an increasingly significant role within the
Group with accelerated growth plans in place in both New Zealand and
Australia. Lumino The Dentists in New Zealand has grown to 49 practices
across the country, with the acquisition of Duncroft Dental in Dunedin in
February 2010. This is in addition to the six practices acquired in the
first half of the 2010 financial year.
In Australia, a further three practices have been added to the Dental
Partners business in the past four months. These include the acquisition of
two dental practices in Coffs Harbour and the opening of a new Greenfield
clinic in Robina.
Following a long standing business and supply relationship with Orthotics
South Island, Abano will today acquire this business and welcome its
principal, Paul Ward, to the Orthotics Group board. This investment expands
the national footprint of Abano's orthotics business, increases the range of
services on offer, and provides income diversification.
Managing director of Abano, Mr Alan Clarke, commented: "At the time of the
sale of Bay Audiology Limited, we indicated that, without Bay Audiology's New
Zealand contribution, our second half year performance would be down on our
first half performance and below previous years, given we had sold a material
part of our business.
"We are in a phase of rebuilding these earnings, primarily through Dental in
the near term, while investing in Audiology in Australia and Asia for the
medium and long term. Progress in Dental is pleasing in both markets and
earnings growth into the second half of the year is strong and positive.
Radiology continues to increase revenue and improve performance. All three
of these sectors are identified as areas for investment growth.
"The pathology business is steady, and we are moving to address the renewal
of the Capital and Coast, and Hutt Valley DHB contract that expires in
eighteen months time.
"However, Brian Injury Rehabilitation work flow and referrals are markedly
down and income has been adversely affected by the ongoing changes with ACC
in recent months. We have restructured the Rehabilitation business and we
are once again reassessing the range of services we offer. A slow down in
ACC approvals has also been noted, partly in Radiology and to a smaller
extent in Orthotics.
"Our joint venture Audiology business in Australia expanded with ten new
Greenfield clinics opened since the beginning of our financial year.
However, we paused our expansion in December as we consolidated these new
clinics. We also noted a down turn in the Office of Hearing Services (OHS)
coupons for hearing devices being approved. This slow down appears to be due
to an administrative process change by OHS, which halved approvals in January
and February. We have since noted that approvals have grown in March and
they are expected to increase to normal levels into April.
"Following the sale of our New Zealand audiology business, we have now been
able to focus on the development of our audiology businesses in Asia. Abano
directors, Peter Hutson and Danny Chan, have just completed an extensive
market visit to Asia and we are now analysing the opportunities identified.
Development into these markets will take time and occur mainly through
Greenfield openings complimented with small selected acquisitions. As a
consequence, positive profit contributions, from our consolidated audiology
businesses, through our new joint venture in Bay International, will only be
apparent in two to three years time, as we develop these opportunities
establishing our brand and expanding our market footprints."
Chairman of Abano, Mrs Alison Paterson, commented: "In the near term and as a
consequence of the temporary slowdown in Australian Audiology and the ACC
referral impacts in Rehabilitation, we are now expecting our second half
earnings to be softer than planned, but core growth continues, primarily from
our two Dental streams.
"We are therefore advising that, before the gain made on the sale of Bay
Audiology Limited in New Zealand, our full year ended 31 May 2010, will see
revenues of $175 to $180 million, operating Earnings Before Interest Tax and
Amortisation (EBITDA) of $18 to $22 million and Net Profit After Tax (NPAT)
of $4.0 to $4.5 million.
"Following our share buy back and cancellation offer, which was under
subscribed, we now have 4.8 million more shares on issue than we planned. As
a consequence our earnings per share will also be lower than planned for the
full financial year.
"Given this, as well as our strong capital structure, lower than planned
levels of debt and our confidence in the mid and long term growth prospects
for Abano, we today announce two initiatives.
"Firstly, for the 2010 financial year, we will alter our annual dividend
policy of 50% NPAT and now maintain last year's dividend per share for this
financial year. This means that a dividend of 21 cents per share will be
paid for the full financial year ended 31 May 2010. In November, we declared
and paid an interim dividend of 7.3 cents per share, excluding the special
interim dividend payment made following the sale of Bay Audiology Limited.
The balance of 13.7 cents per share will be paid in August 2010, and carry
imputation credits.
"Secondly, the board will shortly announce details of an on market, share
buyback programme by the company."
Ends
End CA:00193143 For:ABA Type:FORECAST Time:2010-03-31:08:30:12 More announcements for ABA
|
|


NZX 15 Index
| |
FREE Email News
Today's Market Numbers
| NZX 50 Index |
3350.55 |
 |
23.80 |
| S&P/ASX 200 |
4259.40 |
 |
23.50 |
| Dow Jones Industrials |
12890.50 |
 |
6.50 |
Stock Quote
Most Commented On
|